

NOVADEL PHARMA INC  
Form 8-K  
February 01, 2007

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, DC 20549

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported) January 26, 2007**

**NOVADEL PHARMA INC.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-32177**  
(Commission File No.)

**22-2407152**  
(I.R.S. Employer  
Identification No.)

**25 Minneakoning Road**  
**Flemington, New Jersey 08822**

(Address of principal executive offices) (Zip Code)

Edgar Filing: NOVADEL PHARMA INC - Form 8-K

(908) 782-3431

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers**

On January 26, 2007, the Board of Directors (the Board) of NovaDel Pharma Inc., a Delaware corporation (the Company), on the recommendation of the Compensation Committee of the Board, reviewed its fiscal year 2006 performance and the incentive criteria established by the Board, as well as, the Company's long-term incentive philosophy. Based on that review, the Board awarded bonuses and long-term incentives in the form of options to purchase the Company's common stock to each of the Company's named executive officers as follows:

	<b>Bonus</b>	<b>Option Grant</b>
Dr. Jan H. Egberts	\$116,667	1,250,000
President and Chief Executive Officer Mr. Michael E. Spicer	\$73,200	225,000
Chief Financial Officer and Corporate Secretary		

Option grants are granted in accordance with the Company's 2006 Equity Incentive Plan and have an exercise price equal to \$1.81, the fair market value of a share of the Company's common stock on the grant date (equal to the closing price of the Company's common stock as listed on the American Stock Exchange on the date of grant).

The base salaries of the named executive officers were also established for 2007, and are compared to their 2006 base salaries as follows:

	<b>2006 Base Salary</b>	<b>2007 Base Salary</b>
Dr. Jan H. Egberts	\$350,000	\$350,000
President and Chief Executive Officer Mr. Michael E. Spicer	\$244,000	\$256,200
Chief Financial Officer and Corporate Secretary		

In addition, the Company entered into an amendment to its employment agreement with Mr. Spicer, effective January 26, 2007. The amendment provides that Mr. Spicer will receive additional amounts of money, not to exceed \$25,000 per year, paid for documented relocation expenses and for documented expenses for temporary housing and commuting to and from his residence prior to his relocation through December 2007. Mr. Spicer's employment agreement will expire on December 20, 2007.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**NovaDel Pharma Inc.**

By: /s/ Jan H. Egberts  
Name: Jan H. Egberts  
Title: President and Chief Executive Officer

Date: February 1, 2007